Atherosclerosis in Chronic Kidney Disease: Lessons Learned from Glycation in Diabetes

Medical Clinics of North America

Volumn 96, Issue 1, 2012, Pages 57-65

  Mohar, Dilbahar S ^a,b   Barseghian, Ailin ^a,b   Haider, Nezam ^a,b   Domanski, Michael ^a,b   Narula, Jagat ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Advanced glycated end products; Atherosclerosis; Carbamylation; Cardiovascular disease; Glycation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINO ACID; AMINOKETONE; COLLAGEN; ELASTIN; FIBRIN; FIBRONECTIN; GLUCOSE; LAMININ; LOW DENSITY LIPOPROTEIN; PROTEOGLYCAN; SCLEROPROTEIN;

AMINO TERMINAL SEQUENCE; ATHEROGENESIS; CARBAMOYLATION; CARDIOVASCULAR RISK; CHEMICAL STRUCTURE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; GLYCATION; GLYCEMIC CONTROL; HUMAN; IMMUNOHISTOCHEMISTRY; NEPHROSCLEROSIS; POLYMERIZATION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN PROCESSING; REVIEW;

ATHEROSCLEROSIS; CARBOHYDRATE METABOLISM; CHRONIC DISEASE; DIABETES COMPLICATIONS; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION MEDIATORS; KIDNEY DISEASES; LIPID METABOLISM; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; PLAQUE, ATHEROSCLEROTIC; RISK FACTORS; TUNICA INTIMA;

EID: 84857710351     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2011.11.005     Document Type: Review

References (56)

1. Nakamura Y., Horii Y., Nishino T., et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993, 143(6):1649-1656.
2. Sakata N., Imanaga Y., Meng J., et al. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis 1999, 142(1):67-77.
3. Cerami A., Vlassara H., Brownlee M. Role of nonenzymatic glycosylation in atherogenesis. J Cell Biochem 1986, 30(2):111-120.
4. Gillery P., Monboisse J.C., Maquart F.X., et al. Aging mechanisms of proteins. Diabetes Metab 1991, 17(1):1-16. [abstract only].
5. Vogt B.W., Schleicher E.D., Wieland O.H. ε-Amino-lysine-bound glucose in human tissues obtained at autopsy increase in diabetes mellitus. Diabetes 1982, 31:1123-1127.
6. Palinski W., Koschinsky T., Butler S.W., et al. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol 1995, 15:571-582.
7. Eble A.S., Thorpe S.R., Baynes J.W. Nonenzymatic glucosylation and glucose-dependent cross-linking of protein. J Biol Chem 1983, 258(15):9406-9412.
8. Brownlee M., Cerami A., Vlassara H. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 1988, 4(5):437-451.
9. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 2003, 21(1):3-12.
10. Paul R.G., Bailey A.J. Glycation of collagen: the basis of its central role in the late complications of ageing and diabetes. Int J Biochem Cell Biol 1996, 28(12):1297-1310.
11. Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med 1996, 28(5):419-426.
12. Meng J., Sakata N., Takebayashi S., et al. Glycoxidation in aortic collagen from STZ-induced diabetic rats and its relevance to vascular damage. Atherosclerosis 1998, 136(2):355-365.
13. Kirstein M., Brett J., Radoff S., et al. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci U S A 1990, 87(22):9010-9014.
14. Sakata N., Meng J., Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J Atheroscler Thromb 2000, 7(3):169-176.
15. Gerstein H.C., Miller M.E., Byington R.P., et al. Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD), Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559.
16. Patel A., MacMahon S., Chalmers J., et al. ADVANCE Collaborative Group, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 385(24):2560-2572.
17. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes (VADT). N Engl J Med 2009, 360(2):129-139.
18. Holman R.R., Paul S.K., Bethel M.A., et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577-1589.
19. Lubec G., Pollak A. Reduced susceptibility of nonenzymatically glucosylated glomerular basement membrane to proteases: is thickening of diabetic glomerular basement membranes due to reduced proteolytic degradation?. Ren Physiol 1980, 3(1-6):4-8.
20. Brownlee M., Pongor S., Cerami A. Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen. Role in the in situ formation of immune complexes. J Exp Med 1983, 158(5):1739-1744.
21. Tsilibary E.C. Microvascular basement membranes in diabetes mellitus. J Pathol 2003, 200(4):537-546.
22. Haitoglou C.S., Tsilibary E.C., Brownlee M., et al. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem 1992, 267(18):12404-12407.
23. Tomizawa H., Yamazaki M., Kunika K., et al. Association of elastin glycation and calcium deposit in diabetic rat aorta. Diabetes Res Clin Pract 1993, 19(1):1-8.
24. Winlove C.P., Parker K.H., Avery N.C., et al. Interactions of elastin and aorta with sugars in vitro and their effects on biochemical and physical properties. Diabetologia 1996, 39(10):1131-1139.
25. Tarsio J.F., Reger L.A., Furcht L.T. Decreased interaction of fibronectin, type IV collagen, and heparin due to nonenzymatic glycation. Implications for diabetes mellitus. Biochemistry 1987, 26:1014-1020.
26. Ishida T., Tanaka K. Effects of fibrin and fibrinogen-degradation products on the growth of rabbit aortic smooth muscle cells in culture. Atherosclerosis 1982, 44(2):161-174.
27. Edwards I.J., Wagner J.D., Litwak K.N., et al. Glycation of plasma low density lipoproteins increases interaction with arterial proteoglycans. Diabetes Res Clin Pract 1999, 46:9-18.
28. Little P.J., Ballinger M.L., Osman N. Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis. Vasc Health Risk Manag 2007, 3(1):117-124.
29. Sasaki J., Cottam G.L. Glycosylatin of LDL decreases its ability to interact with high-affinity receptors of human fibroblasts in vitro and decreases its clearance from rabbit plasma in vivo. Biochim Biophys Acta 1982, 713:199-207.
30. Witztum J.L., Mahoney E.M., Branks M.J., et al. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes 1982, 31(4 Pt 1):283-291.
31. Steinbrecher U.P., Witztum J.L. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984, 33:130-134.
32. Hörkkö S., Huttunen K., Antero Kesaniemi Y. Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment. Kidney Int 1995, 47:1732-1740.
33. Gillette P.N., Manning J.M., Cerami A. Increased survival of sickle-cell erythrocytes after treatment in vitro with sodium cyanate. Proc Natl Acad Sci U S A 1971, 68(11):2791-2793.
34. Cerami A. Cyanate as an inhibitor of red-cell sickling. N Engl J Med 1972, 287:807-812.
35. Deiderich D.A., Trueworthy R.C., Gill P., et al. Hematologic and clinical responses in patients with sickle cell anemia after chronic extracorporeal red cell carbamylation. J Clin Invest 1976, 58(3):642-653.
36. Flückiger R., Harmon W., Meier W., et al. Hemoglobin carbamylation in uremia. N Engl J Med 1981, 304:823-827.
37. Chachou A., Randoux C., Millart H., et al. Influence of in vivo hemoglobin carbamylation on HbA1c measurements by various methods. Clin Chem Lab Med 2000, 38:321-326.
38. Jaisson S., Lorimier S., Ricard-Blum S., et al. Impact of carbamylation on type I collagen conformational structure and its ability to activate human polymorphonuclear neutrophils. Chem Biol 2006, 13(2):149-159.
39. Wang Z., Nicholls S.J., Rodriguez E.R., et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007, 13:1176-1184.
40. Stark G.R. Reactions of cyanate with functional groups of proteins. 3. Reactions with amino and carboxyl groups. Biochemistry 1965, 4:1030-1036.
41. Kraus L.M., Kraus A.P. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001, 78:S102-S107.
42. Han J.S., Kim Y.S., Chin H.I., et al. Temporal changes and reversibility of carbamylated hemoglobin in renal failure. Am J Kidney Dis 1997, 30:36-40.
43. Kwan J.T., Carr E.C., Barron J.L., et al. Carbamylated haemoglobin-a retrospective index of time-averaged urea concentration. Nephrol Dial Transplant 1993, 8:565-567.
44. Davenport A., Jones S., Goel S., et al. Carbamylated hemoglobin: a potential marker for the adequacy of hemodialysis therapy in end-stage renal failure. Kidney Int 1996, 50:1344-1351.
45. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286(17):2136-2142.
46. Rudolph T.K., Wipper S., Reiter B., et al. Myeloperoxidase deficiency preserves vasomotor function in humans. Eur Heart J 2011, 1-10.
47. Ok E., Basnakian A.G., Apostolov E.O., et al. Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int 2005, 68:173-178.
48. Garnotel R., Rittié L., Poitevin S., et al. Human blood monocytes interact with type I collagen through alpha x beta 2 integrin (CD11c-CD18, gp150-95). J Immunol 2000, 164(11):5928-5934.
49. Garnotel R., Sabbah N., Jaisson S., et al. Enhanced activation of and increased production of matrix metalloproteinase-9 by human blood monocytes upon adhering to carbamylated collagen. FEBS Lett 2004, 563(1-3):13-16.
50. Rosenberg G.A., Estrada E.Y., Dencoff J.E. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998, 29(10):2189-2195.
51. Hörkkö S., Huttunen K., Kervinen K., et al. Decreased clearance of uraemic and mildly carbamylated low-density lipoprotein. Eur J Clin Invest 1994, 24:105-113.
52. Apostolov E.O., Shah S.V., Ok E., et al. Carbamylated low density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule 1 and vascular cell adhesion molecule 1. Arterioscler Thromb Vasc Biol 2007, 27:826-832.
53. Asci G., Basci A., Shah S.V., et al. Carbamylated low-density lipoprotein induces proliferation and increases adhesion molecule expression of human coronary artery smooth muscle cells. Nephrology 2008, 13(6):480-486.
54. Shah S.V., Apostolov E.O., Ok E., et al. Novel mechanisms in accelerated atherosclerosis in kidney disease. J Ren Nutr 2008, 18(1):65-69.
55. Brownlee M., Vlassara H., Kooney T., et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986, 232:1629-1632.
56. Charonis A.S., Reger L.A., Dege J.E., et al. Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 1990, 39(7):807-814.